Charles River Laboratories International Inc. logo

Charles River Laboratories International Inc.

CRL | NYSE
Chart Builder DCF Calculator
$279.01
+$0.95 (+0.34%)
At close: Sep 21, 2026, 4:00 PM ET
$279.01
$0 (0.00%)
After-hours: Sep 21, 2026, 5:55 PM ET

Company Profile

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Key Executives

Name Position
Birgit Girshick CEO & Director
Glenn G. Coleman Corporate Executive Vice President & Chief Financial Officer
Kerry Dailey Corporate Senior VP & Chief Legal Officer
Mark Mintz Corporate EVP, Chief Information Officer & Global Shared Services
Victoria L. Creamer Corporate Executive Vice President & Chief People Officer
Amy Cianciaruso Corporate Senior Vice President, Chief Communications Officer & Government Relations
Brian F. Bathgate Corporate Senior Vice President of European Safety Assessment
Joseph W. LaPlume Corporate Executive Vice President of Corporate Development & Strategy
Michael Gunnar Knell Corporate Senior Vice President & Chief Accounting Officer
Todd Spencer Corporate Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Aug 27, 2026 4 Filing
Aug 20, 2026 4 Filing
Aug 20, 2026 4 Filing
Aug 20, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 13, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 11, 2026 4 Filing
Aug 11, 2026 4 Filing
Aug 10, 2026 4 Filing
View All SEC Filings
Charles River Laboratories International Inc.
Charles River Laboratories International Inc. logo
Country United States
IPO Date Jun 22, 2000
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 19,000
CEO Birgit Girshick

Contact Details

251 Ballardvale Street Wilmington, Massachusetts 01887 United States

Stock Details

Ticker Symbol CRL
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001100682
CUSIP Number 159864107
ISIN Number US1598641074
SIC Code 8731

© 2026 bestshares.com. All rights reserved.